press releases

• July 7, 2010: NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36
  
• 7. Juli 2010: NOXXON vor Initiierung einer klinischen Phase-Ib-Studie mit dem MCP-1-Inhibitor NOX-E36
  
• June 28, 2010: NOXXON Pharma AG announces management changes
  
• 28. Juni 2010: Wechsel im Vorstand der NOXXON Pharma AG
  
• May 27, 2010: NOXXON Pharma AG raises €33 million in Series D Round
  
• 27. Mai 2010: NOXXON Pharma AG schließt Finanzrunde über 33 Millionen Euro
  
• May 18, 2010: NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer
  
• 18. Mai 2010: NOXXON Pharma AG ernennt Dr. Aram Mangasarian zum Chief Business Officer
  
• May 3, 2010: NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer^® NOX-A 12
  
• 3.Mai 2010: NOXXON's Phase I Studie mit dem Spiegelmer^® NOX-A 12 erfolgreich beendet
  
• December 3, 2009: NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company
  
• 3. Dezember 2009: NOXXON Pharma AG erreicht Meilenstein in der Kooperation mit Eli Lilly and Company
  
• November 2, 2009: NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12
  
• 2. November 2009: NOXXON kündigt den Beginn der ersten klinischen Studie mit dem Blutstammzell-mobilisierenden Spiegelmer NOX-A12 an
  
• October 12, 2009: NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36
  
• 12 Oktober 2009: NOXXON gibt exzellente erste Ergebnisse aus der klinischen Phase I für das Spiegelmer NOX-E36 bekannt
  
• September 3, 2009: NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer^® NOX-A12
  
• 3. September 2009: NOXXON erhält Forschungsförderung für klinische Studien mit Spiegelmer^® NOX-A12
  
• June 8, 2009: NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer
  
• 8. Juni 2009: NOXXON beginnt erste klinische Studie mit einem Spiegelmer
  
• July 8, 2008: NOXXON Pharma announces appointment of Lawrence E. Posner to its Board of Directors
• June 11, 2008: NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly ...
• 11. Juni 2008: NOXXON Pharma AG schließt Kooperationsvertrag mit Eli Lilly über die Entwicklung ...
• April 7, 2008: NOXXON Receives Research Grant from the Federal Ministry of Education and Research
• January 7, 2008: NOXXON Phrama AG appoints Dr. Frank Morich as CEO
• November 9, 2007: NOXXON announces alliance with Roche
• June 8, 2007: NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board
• May 3, 2007: NOXXON Pharma closes Series C Round at Euro 37 million
• February 9, 2007: NOXXON Pharma AG to present at Bio CEO & Investor Conference 2007 in New York
• November 3, 2006: NOXXON Pharma AG to present at Bio-Europe in Duesseldorf, Germany
• November 3, 2006: NOXXON Pharma AG to present at Rodman & Renshaw 8th Annual Healthcare Conference
• October 4, 2006: NOXXON Pharma AG to present at Sachs Associates 6th Annual Biotech in Europe...
• May 12, 2006: NOXXON Pharma AG to present at the Rodman & Renshaw 3rd Annual Global Healthcare...
• May 10, 2006: Change of management at NOXXON Pharma AG
• March 23, 2006: NOXXON Pharma AG announces global strategic alliance with Pfizer. NOX-B11...
• March 15, 2006: NOXXON Pharma AG announces publication of positive animal data with its vasopressin
• March 13, 2006: NOXXON Pharma AG to present at Sachs Associates’ 5th Annual North America Forum...
• February 13, 2006: NOXXON Pharma AG to present at Bio CEO & Investor Conference 2006 in New York